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ABSTRACT: Subcutaneous xenografts represent a popular approach to evaluate eﬃcacy of
prospective molecular therapeutics in vivo. In the present study, the C-14 labeled radioactive
pyrrole−imidazole (Py-Im) polyamide 1, targeted to the 5′-WGWWCW-3′ DNA sequence,
was evaluated with regard to its uptake properties in subcutaneous xenografts, derived from
the human tumor cell lines LNCaP (prostate), A549 (lung), and U251 (brain), respectively.
Signiﬁcant variation in compound tumor concentrations was seen in xenografts derived from
these three cell lines. Inﬂuence of cell line grafted on systemic polyamide elimination was
established. With A549, a marked variation in localization of 1 was determined between
Matrigel-negative and -positive xenografts. An extensive tissue distribution analysis of 1 in
wild-type animals was conducted, enabling the comparison between the xenografts and the
corresponding host organs of origin.
■ INTRODUCTION
Cancer represents a major worldwide health problem, with
nearly 1.6 million new cases estimated to occur in 2014 in the
U.S. alone.1 The past 40 years of research and development of
therapeutics brought improved patients’ survival;2 however,
malignant neoplasias remain the second most common cause of
death in the U.S., accounting for over 20% of all deaths.3
Consequentially, major eﬀorts are being put into the develop-
ment of novel therapeutic approaches.4 Treatment strategies of
various classes are currently available in the clinic. Classical
approaches comprise surgery, chemotherapy, radiation therapy,
and immunotherapy, the method of choice depending on
tumor type and progression stage.5 Cancer chemotherapy has
recently seen important conceptual advances, such as tumor-
speciﬁc tissue targeting,6 prodrug modiﬁcations,7 and develop-
ment of small molecule inhibitors of aberrant signaling nodes in
cancer.8 A signiﬁcant drawback of molecules targeted to tumor-
speciﬁc features is the introduction of evolutionary pressure
upon the cancer cells, which often results in the emergence of
resistant clones.9 Broadly cytotoxic chemotherapeutics (e.g., cis-
platin or doxorubicin) on the other hand commonly exhibit
severe side eﬀects, such as cardiotoxicity,10 neurotoxicity,11 and
neutropenia.12
Pyrrole−imidazole (Py-Im) polyamides are a modular class
of DNA-binding small molecules capable of binding deﬁned
sequences with aﬃnities and speciﬁcities comparable to those
of DNA-binding proteins.13 They are cell-permeable scaﬀolds14
and have been shown to displace various transcription factors
from cognate binding sites,15 leading to altered gene expression
proﬁles. Inhibition of RNA pol II elongation was observed,
accompanied by degradation of the large RNA pol II subunit
and induction of the p53 stress response, without concomitant
DNA damage.16 Most recently, our laboratory has transitioned
to in vivo experimentation, demonstrating bioavailability17 and
eﬃcacy of varying Py-Im polyamides in tumor xenografts
models in mouse.16,18 Antitumor eﬀects with limited systemic
toxicity were observed with the subcutaneous LNCaP prostate
cancer model.16 Our recent C-14 based quantitation study
established signiﬁcant enrichment of a Py-Im polyamide in the
LNCaP tumor xenograft tissue over lung and kidney.19 The
present investigation evaluates the biodistribution of the C-14
radioactively labeled Py-Im polyamide 1 (Figure 1A) in a range
of tumor xenografts, addresses the inﬂuence of xenografted cell
line on systemic polyamide elimination, and provides an
extended biodistribution proﬁle of the molecule.
■ RESULTS
C-14 Radioactively Labeled Py-Im Polyamide 1
Exhibits Diﬀerential Uptake between Tumor Xenografts
of Varying Cellular Origin. Initial experiments compared the
accumulation of compound 1 in LNCaP and A549 subcuta-
neous tumor xenografts (Figure 1A). In order to minimize the
injection-associated experimental error, both tumors were
grafted on the opposing ﬂanks of the same host animal,
following the schedule displayed in Figure SI1 (see
Experimental Section for experimental details). A mean
compound concentration of 1.04 mg/kg (0.74 μM) was
measured for the LNCaP xenograft tissue, comparable with
liver-associated levels of 1.12 mg/kg (Figure 1B). Strikingly,
A549 tumors were found to uptake substantially lower amounts
of polyamide 1 (average of 0.23 mg/kg), closely resembling the
values obtained for the kidney (0.27 mg/kg) and approximately
2-fold higher than lung tissue (0.15 mg/kg). Comparisons with
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the corresponding single-xenograft versions of the experiment
were conducted for both tumor types (Figure 1C). The LNCaP
single tumor experiment revealed a mildly elevated concen-
tration with respect to the double xenograft counterpart (42%,
p < 0.05),19 whereas the values obtained for A549 were not
distinguishable between the two experiment types. Overall, Py-
Im polyamide 1 localized to LNCaP (prostate) tumors at
concentrations 5- to 7-fold higher than those measured with
A549 (lung).
To gain deeper understanding of the phenomenon,
immunohistochemical analyses were conducted, assaying for
tumor-associated microvessels (Figures SI2 and SI3). Micro-
vessel densities were indistinguishable between the two tumor
types. However, LNCaP xenografts were hemorrhagic and
exhibited vascular spaces with extravasated red blood cells at
the microscopic level, which were absent with A549. In order to
broaden the scope of the investigation, the U251 (brain) cell
line was additionally evaluated in the xenograft setting with
regard to uptake of 1 (Figure 2). A mean value of 0.65 mg/kg
(0.47 μM) was measured. The U251-associated xenograft
uptake proﬁle was found to be distinct from both LNCaP and
A549-derived tissues, which were 2.3-fold higher and 2.8-fold
lower, respectively.
None of the tumor-associated levels of Py-Im polyamide 1,
discussed above, exhibited a correlation with tumor size over
the window analyzed (Figure SI4A−D,F).
Host Organ Levels of Py-Im Polyamide 1 as a
Function of the Subcutaneously Grafted Cell Line. The
major host organs kidney, liver, and lung were interrogated with
regard to concentrations of 1 for all xenograft experiments and
benchmarked against the naive background control (Figure 3).
Kidney concentrations spanned a range from 0.22 mg/kg
(naive control and A549 xenograft animals) to 0.27 mg/kg
(double xenograft experiment). Lung tissue showed similar
variance in concentration of 1 as a function of xenografted cell
line (0.12−0.15 mg/kg). A more signiﬁcant diﬀerence was
noted for the liver-associated compound levels. Whereas naive
reference animals were indistinguishable from U251- or A549-
xenograft bearers, grafting of the LNCaP cell line resulted in
liver values that were about 2-fold higher (1.04 mg/kg vs 0.57
mg/kg; p < 0.001).
Matrigel Aﬀects Uptake of Py-Im Polyamide 1 into
A549 Xenografts. We chose to evaluate the inﬂuence of
Matrigel on uptake of 1 for xenografts derived from the A549
cell line. Systematic analysis of tumor polyamide concentration
as a function of size revealed that larger tumors accumulated
substantially higher quantities of compound 1 when Matrigel
was employed during engraftment (Figure SI4F). This was in
striking contrast with the observations made for the same cell
line grafted without Matrigel (Figure SI4A,C). Plotting of
tumor-associated levels of 1 as a function of postengraftment
time revealed a clear trend (Figure 4). At 3 or 4 weeks past
engraftment, there was no statistically signiﬁcant diﬀerence
measurable between the A549 xenografts produced with or
without Matrigel, with an averaged concentration of 0.23 mg/
kg (0.16 μM). Five weeks past engraftment, however, a
divergence became apparent. Whereas Matrigel-negative
tumors showed levels of compound 1 indistinguishable from
earlier time points (0.25 mg/kg), a marked increase was noted
for the Matrigel-positive xenografts. A mean concentration of
0.59 mg/kg was measured (p < 0.001), with the highest value
amounting to 0.89 mg/kg, therewith reaching values com-
parable to those obtained for LNCaP tumors (cf. Figures 1 and
2).
Extended Tissue Distribution Analysis of 1 in Wild-
Type Mice. In order to obtain a more complete picture of
Figure 1. (A) C-14 radiolabeled Py-Im polyamide 1, targeted to the
DNA sequence 5′-WGWWCW-3′. (B) Compound levels of 1 in
LNCaP and A549 tumor xenografts, compared against major host
organs (kidney, liver, lung). Statistical comparison performed against
the LNCaP tumor concentration of 1. (C) Calibration of the dual
xenograft experiment against the respective single-tumor versions. All
injections were performed intraperitoneally at 20 nmol per animal
(NSG male mouse, N = 10) and tissues harvested 24 h following
administration. Each data point represents an individual organ/tumor
analyzed.
Figure 2. Tumor levels of Py-Im polyamide 1 as a function of cell line
engrafted. All injections were performed intraperitoneally at 20 nmol
per animal (NSG male mouse, N = 10) and tissues harvested 24 h
following administration. Each data point represents an individual
tumor analyzed. Statistical comparison was performed against the
U251 tumor concentration of 1.
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biodistribution of Py-Im polyamide 1, a comprehensive tissue
analysis following administration of 1 was conducted in the
balb/c mouse strain. Blood, bone marrow (BM), brain, fat
tissue, intestinal tissue, heart, kidney, liver, lung, muscle,
pancreas, prostate, and spleen were interrogated independently
(Figure 5 and Table SI1). Because the balb/c male mouse of
comparable age possesses a body weight that is reduced by
some 25% with regard to its NSG counterpart, compound 1
was administered at 15 nmol per animal here, as opposed to 20
nmol per animal employed with NSG mice.
The majority of tissues exhibited concentrations of 1 below
0.1 mg/kg, with the brain not showing any signiﬁcant evidence
of polyamide uptake. Kidney and liver were found to contain
comparable compound levels to those determined for the NSG
strain (0.23 mg/kg vs 0.22 mg/kg and 0.57 mg/kg vs 0.49 mg/
kg for kidney and liver, respectively). Interestingly, bone
marrow concentration of 1 amounted to 0.24 mg/kg, therewith
being over 10-fold higher than blood. The spleen exhibited a
concentration of 1 of 0.32 mg/kg, whereas the pancreas
contained compound 1 at 0.15 mg/kg. The majority of organs
contained the Py-Im polyamide 1 at concentrations that were
signiﬁcantly lower than those determined for any of the tumor
xenografts examined above.
■ DISCUSSION
The xenograft approach is a popular method to interrogate a
prospective antitumor agent in vivo.20 It can be subdivided into
two main categories, namely, subcutaneous (ectopic) and
orthotopic xenografts. Orthotopic inoculation is considered to
recapitulate the tumor setting more closely than the
subcutaneous approach because cancer cells are grafted into
the host organ of tumor origin. With the exception of lung and
blood cancer, for which orthotopic xenografts are readily
achievable by tail vein injection, the approach is experimentally
demanding and requires sophisticated survival surgery.
Genetically engineered animal tumor models represent an
attractive alternative to xenograft experimentation, since they
tend to recapitulate certain aspects of disease progression, such
as tumor vascularization, tumor−stroma interactions, and
metastasis formation, more accurately.21 They furthermore
allow conducting experiments in immunocompetent animals.
The studies are, however, elaborate to perform, requiring
extended experimentation time frames and large animal group
sizes. Furthermore, xenografts allow the assessment of eﬃcacy
against human cancer cell lines and primary cells, whereas
genetically engineered animal models are limited to neoplasias
of the species employed. Given the above, subcutaneous
xenografts remain an attractive method to generate initial
estimates of eﬃcacy for molecules of interest.22
The present study was initiated to rationalize the apparent
discrepancy between cell culture results and the corresponding
xenograft experiments that we observed in preceding
Figure 3. Concentrations of polyamide 1 in the host organs kidney
(A), liver (B), and lung (C) as a function of cell line engrafted. Naive
indicates reference host animals devoid of tumor graft. All injections
were performed intraperitoneally at 20 nmol per animal (NSG male
mouse, N = 10) and tissues harvested 24 h following administration.
Each data point represents an individual organ analyzed.
Figure 4. A549 tumor levels of Py-Im polyamide 1 as a function of
time (3−5 weeks), presence of the LNCaP tumor on the opposite
ﬂank (denoted as d.f.), and Matrigel used to engraft (±MG). All
injections were performed intraperitoneally at 20 nmol per animal
(NSG male mouse) and tumors harvested 24 h following
administration. Each data point represents an individual tumor
analyzed: |(∗∗∗) p < 0.001|.
Figure 5. Extended tissue distribution analysis of Py-Im polyamide 1
in wild-type mice. Injections were performed intraperitoneally at 15
nmol per animal (balb/c male mouse) and organs harvested 24 h
following administration. Error bars represent standard deviations (N
= 5). BM denotes bone marrow. Dashed line indicates the 0.1 mg/kg
threshold.
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investigations.16b,18a Speciﬁcally, in vitro cytotoxicity evaluation
for the nonradioactive analogue of 1 revealed A549 and LNCaP
to possess comparable sensitivities toward polyamide treatment
(IC50 values of 1.5 ± 0.2 μM and 2.1 ± 0.3 μM,
16b
respectively). This contrasted with the outcome of our in
vivo investigations, with LNCaP xenografts exhibiting tumor
burden reduction in response to treatment with 1 in the
xenograft setting,16b while related studies with the A549 cell
line were unsuccessful.18a The present investigation demon-
strates this unanticipated result to be rooted, at least in part, in
the pronounced diﬀerence in polyamide uptake between the
two xenograft types, LNCaP tumors accumulating the
compound at 5- to 7-fold higher levels than their A549
counterparts (Figure 1) in both the dual and the single
xenograft experiments conducted with A549 and LNCaP,19
respectively. Additional discrepancy may stem from the
diﬀerence in the time frame employed for in vitro cytotoxicity
measurement (3 days) and in vivo antitumor evaluation (at
least 7 days) and the fact that the polyamide concentration is
kept constant over the course of the experiment in vitro but not
in vivo.19
Comparison with U251 xenografts revealed an uptake proﬁle
that was distinct from both LNCaP- and A549-derived tumors
(Figure 2). This leads to the important realization that neither
LNCaP nor A549 could be considered an outlier. Each cell line
examined yielded tumors with characteristic uptake features,
which, while clearly dependent on the cell line grafted, could
not have been predicted from in vitro experiments. The U251-
derived xenografts exhibited higher microvessel densities than
both A549 and LNCaP tumors, without however possessing the
vascular spaces characteristic of LNCaP.23 This likely gave rise
to distinct characteristics of U251 tumors.
It was surprising to ﬁnd that liver accumulation of 1 was
dependent on the cell line grafted. Whereas the grafting of
A549 or U251 cells showed no inﬂuence, the presence of
LNCaP-derived tumors resulted in levels that were elevated by
about 2-fold (Figure 3). This was possibly due to the increased
leakiness of the tumor vasculature in LNCaP xenografts, as
compared with A549 (Figure SI 2) and U251.23 Matrigel-
positive xenografts did not result in increased liver compound
values as compared to their Matrigel-negative counterparts
(0.65 mg/kg vs 0.55 mg/kg, p = 0.17). It is possible that the
leaky LNCaP tumor vasculature creates liver stress, which in
turn could result in impeded clearance of Py-Im polyamide 1.
This phenomenon is likely to operate with other types of small
molecule therapeutics, although the magnitude of the eﬀect will
be dependent on speciﬁcs, which could lead to alternative
clearance mechanisms.
The inﬂuence of Matrigel on uptake of 1 by A549 xenografts
was of interest due to the common use of Matrigel to facilitate
engraftment of tumor cells in vivo.24 An eﬀect indeed became
manifest, albeit only at the most advanced postengraftment
time points (Figure 4 and Figure SI4E). It appears likely that
the A549 tumor architecture diverges at advanced time points,
as a function of Matrigel. Supporting this, slightly higher
weights were noticed in the Matrigel-positive group than in the
Matrigel-negative control at the point of divergence (average of
409 mg vs 271 mg; p < 0.05). Inﬂuence of Matrigel
employment on tumor proliferation, vascularization, and
metastasis has been previously documented.24 The xenograft
host−tumor interface being artiﬁcial a priori, it is unclear
whether the Matrigel-positive or -negative tumors give rise to
more accurate models.
Comparisons of uptake between tumors and the correspond-
ing healthy host tissues were of interest in order to probe for
potential enrichment in cancer lesions. Organ tissues were
derived from wild-type mice of the balb/c strain. This strain is
likely to oﬀer a superior representation of healthy organs than
its heavily immunosuppressed NSG counterpart. The LNCaP
xenografts exhibited concentrations ranging from 0.5 to 2.0
mg/kg, thus being an order of magnitude higher than what was
determined for mouse prostate, which possessed an averaged
value below 0.1 mg/kg. It is therefore possible that the
compound quantities measured in LNCaP subcutaneous
xenografts provide optimistic estimates. However, tumor
formation does perturb organ integrity, and it therefore appears
likely that diseased prostate tissue should exhibit values
diﬀerent from the healthy organ in both the orthotopic and
the genetically induced disease model setting. It should
furthermore be noted that LNCaP was derived from a
metastatic lymph node lesion, which, although having
originated from a prostate tumor, likely possessed a distinct
architecture. Tumors derived from the A549 cell line (nonsmall
lung carcinoma) can be compared with lung tissue concen-
trations of 1. With exception of the elevated values that were
determined in Matrigel-positive tumors at extended time
points, they averaged at approximately 0.2 mg/kg, whereas
healthy lung tissue exhibited concentrations of 1 of around 0.1
mg/kg. Whether this is a coincidence or indeed evidence that
A549 xenografts mimic the lung tissue setting more adequately
remains unclear. Lung colonization experiments may be useful
to shed further light onto this question in future studies. U251
is a glioblastoma-derived cell line, and the healthy organ of
origin is the brain. The corresponding comparison between
tumor and tissue of origin lacks substance, since the
subcutaneous xenograft cannot be expected to recapitulate
the blood−brain barrier. Overall, and keeping the above-
mentioned caveats in mind, tumors generally accumulated
higher amounts of compound 1 than the corresponding healthy
tissues of origin.
■ CONCLUSIONS
Our investigation gave insight into the intricacies of various
important aspects of tumor xenograft experimentation. The
present study identiﬁed a marked diﬀerence in xenograft uptake
levels of Py-Im polyamide 1 in the three cell lines tested.
LNCaP-derived tumors exhibited a mean concentration of the
polyamide that was over 5-fold higher than the corresponding
A549-associated value. Compound 1 was found to localize to
U251 xenografts at a concentration that was substantially lower
than what was found for LNCaP but signiﬁcantly higher than
A549. This demonstrates the necessity to examine uptake into
tumor xenografts on a case by case basis in order to rationalize
outcomes of antitumor studies and to identify viable cell lines
for future xenograft experiments. Unexpectedly, elimination of
1 from the liver was impaired in LNCaP xenograft-bearing
animals. Matrigel was found to inﬂuence uptake of 1, resulting
in a 2-fold elevation at longer postengraftment time points with
A549-derived tumors. Comparison with the corresponding
healthy tissues revealed that higher concentrations of 1 were
associated with xenografts, animal prostate tissue exhibiting
order of magnitude lower values than those measured with
LNCaP tumors.
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■ EXPERIMENTAL SECTION
Polyamide Synthesis and Characterization. The synthesis of
polyamide 1 has been previously reported.19 The compound was
conﬁrmed by analytical HPLC to possess a purity of >99% and
coeluted with its nonradioactive analog. Polyamide 1 was quantitated
employing liquid scintillation with the activity constant of 55 mCi/
mmol, which was provided by the vendor (ARC). Quench correction
was conducted against a standard curve that was reported by our
laboratory in a preceding account.19
Cell Culture Maintenance and Xenograft Establishment. The
cell lines A549, LNCaP, and U251 were obtained from ATCC and
cultured following provider’s recommendations, not exceeding passage
number 25. Cells were only employed for xenograft experimentation
where a viability of 95% or higher was recorded (trypan blue stain).
Nod-SCID-Gamma (NSG) male mice were purchased at 8 weeks of
age from JAX and housed in an immunocompromised facility (level A)
in accordance with IACUC regulations. They were taken forward for
experiments after an acclimatization period of at least 3 days. All
engraftments were conducted subcutaneously with 2.5 M cells per
inoculation in 200 μL vehicle (either media or 1:1 mixture with
Matrigel). Animals were monitored weekly for signs of pain and
distress. Male balb/c mice were obtained from JAX and housed in a
level B animal facility.
Administration of Polyamide 1 and Tissue Harvest.
Compound 1 was quantitated by liquid scintillation counting prior
to injection and administered intraperitoneally at either 20 nmol
(NSG) or 15 nmol (balb/c) per animal in a fume hood dedicated
exclusively to C-14 in vivo radioexperimentation. Animals were housed
in disposable cages and euthanized by CO2 asphyxiation. Disposable
cages were destroyed at the end of the experiment. Tissues were
harvested, placed into scintillation vials, and solubilized at +65 °C for
at least 12 h employing the proprietary dissolution agent SOLVABLE
(PerkinElmer). The resultant solutions were decolorized with 2 × 200
μL hydrogen peroxide (30%, Sigma-Aldrich) at ambient temperature
for at least 2 h, followed by heating to +65 °C for 30 min. Samples
were treated with 10 mL of the scintillation cocktail HIONIC-FLUOR
(PerkinElmer), vortexed and the amounts of C-14 quantitated by
liquid scintillation counting at the Beckman Coulter LS6500
multipurpose scintillation counter. All reported values have been
quench-corrected and normalized against organ weight. Bone marrow
weights were calculated as the diﬀerence between the femur and tibia
bones subjected to tissue solubilization and the insoluble residue,
which was isolated subsequent to C-14 quantitation. In order to obtain
dry bone residues, the scintillation ﬂuid was decanted and the solids
were triturated (twice with ethanol, then three times with MeOH) and
dried at +65 °C overnight. Two-tailed t-tests assuming unequal
variance were applied to all data sets.
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